bionomics is a biopharmaceutical company dedicated to making better treatments for cancer, central nervous system disorders such as anxiety, depression and alzheimer's disease. our exceptionally talented team is driven by a shared commitment to make a difference in diseases with inadequate treatment options. we are in a strong growth phase with our world-class portfolio of promising drug candidates from early to advanced stages of clinical development. this portfolio is fed by highly productive drug discovery platforms which includes multicore®, our proprietary chemistry capability. at the core of our business is strategic partnering. we partner with large pharmaceutical companies to get our drugs through the later stages of development and into the market as rapidly as possible. this means we can focus our strengths in innovative drug discovery to extract as many "shots on goal" from our diverse pipeline in the quest to create the world's new blockbuster drugs. we have a passion for
Company profile
Ticker
BNOX, BNOX-MM
Exchange
Website
Employees
Incorporated
Location
Industry (SIC)
SEC CIK
BNOX stock data
Latest filings (excl ownership)
6-K
Half-Year Report – 31 December 2023
15 Mar 24
UPLOAD
Letter from SEC
18 Jan 24
20-F/A
2023 FY
Annual report (foreign) (amended)
17 Jan 24
CORRESP
Correspondence with SEC
11 Jan 24
UPLOAD
Letter from SEC
8 Jan 24
6-K
Current report (foreign)
4 Jan 24
6-K
Results of Annual General Meeting
30 Nov 23
6-K
Bionomics Announces Retirement of Board Member
28 Nov 23
6-K
Notice of Annual General Meeting Explanatory Statement and Proxy Form
3 Nov 23
20-F
2023 FY
Annual report (foreign)
18 Oct 23
Latest ownership filings
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
Lynx1 Capital Management LP
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G
Lynx1 Capital Management LP
30 Oct 23
SC 13G
TANG CAPITAL PARTNERS LP
10 Oct 23
SC 13G
Point72 Asset Management, L.P.
29 Sep 23
SC 13G
BIOTECHNOLOGY VALUE FUND L P
14 Feb 22
SC 13D
Apeiron Investment Group Ltd.
30 Dec 21
Financial summary
Quarter (USD) | Jun 23 | Jun 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 3 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 5.75 bn |
Total shares | 402.81 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Apeiron Investment | 402.55 mm | $5.17 bn |
Point72 Asset Management | 126.00 k | $277.20 mm |
BVF | 80.97 k | $178.14 mm |
Woodline Partners | 54.45 k | $119.78 mm |
Proequities | 0.00 | $0.00 |
News
12 Health Care Stocks Moving In Tuesday's After-Market Session
2 Apr 24
HC Wainwright & Co. Reiterates Buy on Bionomics, Maintains $8 Price Target
21 Mar 24
Bionomics Reveals Detailed Data From PTSD Trial, Stock Soars
21 Mar 24
12 Health Care Stocks Moving In Monday's Pre-Market Session
22 Jan 24
Bionomics Provided A 2023 Review And Its Outlook For 2024
22 Jan 24